Shattuck Labs, Inc.
$7.88
▲
2.72%
2026-04-21 09:39:02
www.shattucklabs.com
NMS: STTK
Explore Shattuck Labs, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$538.88 M
Current Price
$7.88
52W High / Low
$7.68 / $0.71
Stock P/E
—
Book Value
$1.3
Dividend Yield
—
ROCE
-61.34%
ROE
-60.25%
Face Value
—
EPS
$-0.7
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
40
Beta
1.29
Debt / Equity
2.94
Current Ratio
11.7
Quick Ratio
11.7
Forward P/E
-14.49
Price / Sales
523.03
Enterprise Value
$419.58 M
EV / EBITDA
-8.79
EV / Revenue
419.58
Rating
None
Target Price
$10
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | ARS Pharmaceuticals, Inc. | $8.18 | — | $812.25 M | — | -62.2% | -92.33% | $18.9 / $6.66 | $1.15 |
| 2. | Rhythm Pharmaceuticals, Inc. | $87.72 | — | $5.99 B | — | -51.31% | -90.45% | $122.2 / $55.31 | $2.07 |
| 3. | Alpha Cognition Inc. Common Stock | $6.89 | — | $150.02 M | — | -23.03% | -40.68% | $11.54 / $3.97 | $2.88 |
| 4. | Benitec Biopharma Inc. | $13.99 | — | $483.71 M | — | -42.71% | -33.5% | $17.15 / $9.85 | $5.47 |
| 5. | Maze Therapeutics, Inc. | $26.84 | — | $1.4 B | — | -38.15% | -47.52% | $53.65 / $7.16 | $7.2 |
| 6. | OmniAb, Inc. | $1.55 | — | $237.44 M | — | -24.23% | -23.36% | $2.29 / $1.22 | $1.85 |
| 7. | Veradermics, Incorporated | $73.97 | — | $2.85 B | — | -49.88% | -72.06% | $80.9 / $32 | $-131.48 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | |
|---|---|---|---|---|---|
| Sales | 0 M | 1 M | 0 M | 0 M | 0 M |
| Operating Profit | -13.37 M | -10.72 M | -13.03 M | -14.39 M | -19.64 M |
| Net Profit | -12.59 M | -10.06 M | -12.46 M | -13.7 M | -18.68 M |
| EPS in Rs | -0.17 | -0.13 | -0.16 | -0.18 | -0.25 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 1 M | 5.72 M | 1.66 M | 0.65 M |
| Operating Profit | -51.51 M | -80.57 M | -91.96 M | -103.33 M |
| Net Profit | -48.81 M | -75.41 M | -87.3 M | -101.94 M |
| EPS in Rs | -0.65 | -1 | -1.16 | -1.35 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 91.03 M | 91.05 M | 159.56 M | 205.32 M |
| Total Liabilities | 8.64 M | 11.42 M | 14.86 M | 29.17 M |
| Equity | 82.39 M | 79.63 M | 144.71 M | 176.16 M |
| Current Assets | 82.47 M | 79.22 M | 143.22 M | 184.58 M |
| Current Liabilities | 7.05 M | 8.92 M | 11.45 M | 24.96 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -39.88 M | -60.52 M | -81.23 M | -94.5 M |
| Investing CF | -7.89 M | -8.51 M | 110.86 M | 49.44 M |
| Financing CF | 44.57 M | 0.79 M | 48.62 M | 0.17 M |
| Free CF | -39.95 M | -60.57 M | -81.64 M | -106.11 M |
| Capex | -0.07 M | -0.06 M | -0.41 M | -11.61 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 245.26% | 154.14% | — | — |
| Earnings Growth % | 13.62% | 14.37% | — | — |
| Profit Margin % | -1318.13% | -5268.44% | -15635.74% | — |
| Operating Margin % | -1408.27% | -5549.61% | -15848.01% | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | -1341.34% | -5305.67% | -15376.69% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.